AbbVie (ABBV) Common Equity (2012 - 2026)

AbbVie (ABBV) has 15 years of Common Equity data on file, last reported at -$6.6 billion in Q1 2026.

• Common Equity for Q1 2026 came in at -$6.6 billion, down 552.26% year-over-year; the trailing twelve-month figure through Mar 2026 was -$6.6 billion (down 552.26% YoY), and the FY2025 annual result was -$3.2 billion, down 195.96% from the prior year.
• Common Equity eased to -$6.6 billion in Q1 2026 per ABBV's latest filing, from -$3.2 billion in the prior quarter.
• Over five years, Common Equity peaked at $17.3 billion in Q4 2022 and troughed at -$6.6 billion in Q1 2026.
• A 5-year average of $7.4 billion and a median of $8.0 billion in 2024 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2026: Common Equity gained 18.79% in 2022, then slumped 552.26% in 2026.
• A 5-year view of Common Equity shows it stood at $17.3 billion in 2022, then tumbled by 39.86% to $10.4 billion in 2023, then plunged by 67.64% to $3.4 billion in 2024, then slumped by 195.96% to -$3.2 billion in 2025, then slumped by 104.83% to -$6.6 billion in 2026.
• Business Quant data shows ABBV's Common Equity at -$6.6 billion in Q1 2026, -$3.2 billion in Q4 2025, and -$2.6 billion in Q3 2025.